Picture of Eris Lifesciences logo

ERIS — Eris Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

India's Lupin, Eris Lifesciences gain on insulin market share prospects

** India's Lupin LUPN.NS and Eris Lifesciences ERIS.NS rise about 2% each

** Macquarie says both pharmaceutical cos well-positioned to gain market share in India's insulin market after report suggests Novo Nordisk NOVOb.CO may discontinue some key brands in India

** Novo Nordisk is discontinuing India's largest selling insulin, Human Mixtard, among other older insulin brands in India, as per a Times of India report earlier this week

** LUPN on course for fifth consecutive session of gains, while ERIS rises for third day in a row

** Assuming the two companies capture Novo's vacated market share equally, it could mean ~10% revenue upside for ERIS and ~1% for LUPN - Macquarie

** Brokerage has "outperform" rating on LUPN and ERIS

** YTD, LUPN down 8.8%, while ERIS up 10.8%

 (Reporting by Vivek Kumar M)

 ((VivekKumar.M@thomsonreuters.com;))

Recent news on Eris Lifesciences

See all news